Skip to content
DataLookout
Menu

SWAP-7NCT06691191

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

StatusRecruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 14 words
    • Primary completion pushed from Aug 31, 2026 to Dec 31, 2026
    • Study completion pushed from Dec 31, 2026 to Apr 30, 2027
    • Study description revised
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2025 to Jan 8, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Platelet reactivity measured by VerifyNow
Timeframe: 21±7 days

Arms and interventions

Ticagrelor monotherapyActive comparator

Ticagrelor 90 mg bid monotherapy for 21±7 days

Prasugrel monotherapyExperimental

Prasugrel 10 mg qd for 21±7 days

Drugs: Ticagrelor 90 mg, Prasugrel 10 mg

Sites

1 site in 1 country

  • University of Florida JacksonvilleJacksonville, Florida, United States